Is a Defibrillator Used for Atrial Fibrillation?

Defibrillators are used for atrial fibrillation, but not in the way most people picture. The dramatic unsynchronized shock delivered during cardiac arrest is a different procedure from what happens when a doctor uses a defibrillator to treat AF. Instead, the device is set to a synchronized mode that carefully times the electrical pulse to a safe point in the heart’s electrical cycle, a procedure called electrical cardioversion. This distinction matters more than it sounds, because getting the timing wrong can turn a survivable rhythm problem into a life-threatening one.

How Electrical Cardioversion Differs From Emergency Defibrillation

When someone collapses in ventricular fibrillation or pulseless ventricular tachycardia, rescuers deliver an unsynchronized shock as fast as possible. The heart’s electrical activity is so chaotic that timing is irrelevant; the goal is simply to reset everything at once. In atrial fibrillation, the ventricles are still beating, just irregularly. The heart has a brief vulnerable window during each beat cycle, corresponding to a feature on the electrocardiogram called the T wave, where a poorly timed shock could push the ventricles into fibrillation. Synchronized cardioversion avoids that window by detecting the heart’s own QRS complex and delivering energy only at a safe moment.

Case reports illustrate what happens when synchronization fails. If the device accidentally locks onto the T wave instead of the QRS complex, the shock can trigger ventricular fibrillation, an immediately dangerous rhythm requiring emergency resuscitation.¹ This risk is well recognized and is the entire reason the synchronization feature exists.² In practice, the complication is rare when the equipment is used correctly, but it underscores why cardioversion for AF is performed in a controlled medical setting with a full resuscitation team standing by.

How Well Does Electrical Cardioversion Work

Electrical cardioversion converts AF back to a normal sinus rhythm in over 90% of cases, making it the most reliable acute method for restoring normal heart rhythm.³ It has been used clinically for over 40 years and is considered safe and reliable, particularly in emergencies where AF is causing dangerously low blood pressure or other signs of instability.⁴

A large real-world study of over 400 cardioversion cases performed in an emergency department found a success rate of about 96%.⁵ Age made a notable difference: success was 100% in patients aged 18 to 39 but dropped to around 69% in those over 80.⁵ Duration of AF also matters. The longer the heart has been fibrillating, the more the atrial tissue remodels electrically and structurally, making it harder to shock back into a normal rhythm.

Biphasic Versus Monophasic Shocks

Modern defibrillators use biphasic waveforms, meaning the electrical current flows in one direction and then reverses. Older devices used monophasic waveforms that pushed current in only one direction. For atrial fibrillation, the difference is significant. In a multicenter trial, a first biphasic shock at just 70 joules successfully cardioverted 68% of patients, while a first monophasic shock at 100 joules worked in only 21%. After the full protocol, the biphasic approach succeeded in 94% of cases versus 79% for monophasic, and it achieved those results with half the delivered current.⁶

Another international trial confirmed these findings at matched energy levels. At 100 joules, biphasic shocks converted 60% of patients compared to 22% with monophasic. At 200 joules, the gap was 90% versus 53%. Biphasic patients also needed fewer shocks overall and had less skin irritation afterward.⁷ When escalation protocols were used (stepping up energy with each attempt), both waveforms eventually reached about 90% success, but biphasic got there with roughly half the total energy delivered.⁸ Lower energy means less discomfort, less sedation needed, and less risk of skin burns, which is why biphasic devices have become standard.

Why an AED Will Not Shock Atrial Fibrillation

Automated external defibrillators, the devices found in airports and gyms, are designed to treat cardiac arrest caused by ventricular fibrillation or ventricular tachycardia. They analyze the heart’s rhythm and advise a shock only for rhythms where the heart is not effectively pumping. A person in atrial fibrillation typically still has a pulse, even though the rhythm is irregular. AEDs are programmed to recognize this difference, and testing has confirmed that no shocks are advised for atrial fibrillation, atrial flutter, or other supraventricular rhythms.⁹

This is by design. An unsynchronized shock from an AED delivered to someone in AF could hit during the vulnerable T-wave period and cause ventricular fibrillation. AEDs lack the synchronization circuitry and the clinical judgment needed to safely cardiovert AF. If you find someone conscious but complaining of a racing, irregular heartbeat, the AED is not the right tool. They need medical evaluation, not a shock from a public-access device.

Blood Clot Risk and Anticoagulation

One of the biggest concerns with cardioversion for AF is not the shock itself but what can happen afterward. During atrial fibrillation, the atria quiver rather than contract properly, allowing blood to pool and potentially form clots, particularly in a pouch called the left atrial appendage. If a shock restores normal rhythm and the atria suddenly start contracting again, any clot that formed during AF can be ejected into the bloodstream, causing a stroke.

Current guidelines address this risk with a clear rule: if AF has lasted longer than 48 hours, or if the duration is unknown, patients need at least three weeks of anticoagulation therapy before cardioversion and at least four weeks afterward.¹⁰ This applies regardless of whether the cardioversion is performed electrically or with medication.¹¹ An alternative approach is to perform a transesophageal echocardiogram (a specialized ultrasound that looks at the heart from inside the esophagus) to check for clots before proceeding. If no clot is seen, cardioversion can happen sooner.

For AF lasting less than 48 hours, the clot risk is lower, and cardioversion can often proceed without the prolonged anticoagulation lead-in. This is one reason emergency physicians sometimes cardiovert acute-onset AF right in the emergency department. But even after apparently quick-onset AF, post-cardioversion anticoagulation is still recommended because the risk doesn’t disappear the moment normal rhythm is restored.

Atrial Stunning After Cardioversion

Even after a successful shock, the atria don’t immediately spring back to full function. A phenomenon called atrial stunning occurs after cardioversion, where the atrial muscle regains its electrical rhythm but temporarily loses its mechanical squeeze. The atria look like they are beating on an ECG, but echocardiography reveals they are barely contracting. This sluggish function is what keeps the clot risk elevated for weeks after the procedure and is the reason anticoagulation continues post-cardioversion.¹²

Research has shown that stunning can be partially reversed by pacing the heart at faster rates or by administering certain medications, suggesting that the contractile machinery is still intact but temporarily unresponsive.¹³ The degree of stunning tends to be worse after longer episodes of AF and after cardioversion of atrial fibrillation compared with atrial flutter.¹⁴ Full mechanical recovery can take days to weeks.

Electrical Cardioversion Versus Drug Therapy

Electrical cardioversion is not the only option for restoring sinus rhythm. Certain antiarrhythmic drugs can also convert AF, an approach known as pharmacological cardioversion. The two approaches have distinct trade-offs. Electrical cardioversion works in over 90% of cases and restores rhythm almost instantly. Drug therapy converts about 50 to 70% of recent-onset AF episodes, and the time to conversion is unpredictable, sometimes taking several hours.³ For AF that has persisted longer than a few days, drugs rarely work.

The main advantage of drug therapy is that it avoids sedation. Electrical cardioversion requires brief general anesthesia or deep sedation because the shock is painful. This introduces its own set of risks, including temporary drops in blood pressure and breathing difficulties.¹⁵ On the other hand, antiarrhythmic drugs carry the risk of proarrhythmia, meaning they can paradoxically trigger new dangerous rhythms.¹⁶ In unstable patients whose blood pressure is crashing because of AF, electrical cardioversion is the clear first choice because waiting hours for a drug to work isn’t an option.

Sedation and What to Expect During the Procedure

If you’re scheduled for an elective cardioversion, the procedure is relatively quick. After fasting for several hours, you’ll have an IV placed and adhesive electrode pads applied to your chest (and sometimes your back). A short-acting sedative is administered so you’re unconscious for the shock but wake up within minutes. The most commonly used agents are propofol and midazolam. Studies comparing the two have found similar safety profiles, though propofol tends to cause a bigger temporary drop in blood pressure.¹⁷ Roughly a quarter of patients experience some minor side effect during the sedation, such as brief slowing of the heart rate or a dip in oxygen levels, but these are typically managed easily without any need for advanced interventions.¹⁵

Most people remember nothing of the shock itself. Some report mild chest soreness or redness at the pad sites for a day or two afterward. The entire procedure, from sedation to waking up, often takes less than 30 minutes. Many patients go home the same day.

Implantable Defibrillators and Their Relationship to AF

Implantable cardioverter-defibrillators (ICDs) are surgically placed devices designed primarily to treat life-threatening ventricular arrhythmias. They monitor the heart continuously and deliver an internal shock if they detect ventricular fibrillation or fast ventricular tachycardia. AF enters the picture in two ways: as something ICDs can detect, and as something that complicates their function.

Dual-chamber ICDs can detect atrial fibrillation with high accuracy. One study of 80 patients found the device correctly identified 98% of AF episodes.¹⁸ This detection capability helps doctors monitor how often AF occurs and tailor treatment accordingly. Some dual-chamber ICDs can even attempt to cardiovert AF internally, though the evidence on this is mixed. One study found that internal cardioversion of persistent AF by an ICD had a low success rate, and the authors recommended preferring external cardioversion when persistent AF needs to be terminated.¹⁹

There is also evidence that patients who have both AF and heart failure may actually derive greater benefit from having an ICD. AF contributes to dangerous ventricular rhythms through several mechanisms, including irregular conduction patterns and the effects of rate-controlling medications, which means patients with AF may face a higher baseline risk of the exact arrhythmias an ICD is designed to catch.²⁰

Dedicated Atrial Defibrillators

Engineers have explored building ICDs specifically designed to shock atrial fibrillation. These devices recognize AF episodes and deliver a relatively low-energy internal shock to the atria. The concept works: published data show that atrial ICDs terminate AF in roughly 76 to 90% of attempts, with good discrimination between atrial and ventricular rhythms and no triggering of dangerous ventricular arrhythmias.²¹

The problem is pain. Unlike ventricular defibrillation, where the patient is unconscious during cardiac arrest and feels nothing, atrial shocks hit a conscious patient. Even low-energy internal shocks are unpleasant enough that many patients with these devices avoid using them. Some designs let the patient trigger the shock at a convenient time (after taking a sedative, for example), but this approach leads to underuse. As a result, dedicated atrial defibrillators account for only about 2% of all ICDs implanted.²¹ Catheter ablation has largely overtaken this approach as the preferred non-drug therapy for recurrent AF.

Wearable Defibrillators and AF-Related False Alarms

Wearable cardioverter-defibrillators are vest-like devices prescribed to patients at temporary risk of sudden cardiac death, such as those waiting for an ICD implant or recovering from a heart attack. These devices are designed to shock ventricular arrhythmias, not AF. But AF can fool them. A study of inappropriate shocks from wearable defibrillators found that atrial fibrillation was the single most common cause, responsible for about a third of all false alarms.²² The rapid, irregular ventricular rate during AF can mimic the rate signatures the device is looking for. This is a genuine concern because inappropriate shocks are painful, psychologically distressing, and may themselves carry cardiac risk.

Recurrence After Cardioversion

Successful cardioversion does not mean AF is cured. The rhythm often returns. How quickly it comes back varies widely, and predicting recurrence remains an active area of research. One study found that markers of inflammation in the blood were the strongest independent predictor of recurrence. Patients with the lowest levels of C-reactive protein (a common inflammatory marker) had AF recurrence rates of only 4% at three months and 28% at one year, compared with 33% and 60% in patients with higher levels.²³ This suggests that the underlying atrial inflammation and remodeling driving AF persists even after the rhythm is electrically corrected.

Newer research is exploring whether patterns in the heart’s electrical signals, measured just after cardioversion, can predict who will relapse. Specific features extracted from vectorcardiography recordings have shown promising accuracy in identifying patients at high risk of recurrence.²⁴ If these tools mature, they could help doctors decide which patients are likely to stay in normal rhythm and which should skip straight to more durable therapies like catheter ablation.

The high recurrence rate feeds into a broader clinical debate about whether aggressively restoring sinus rhythm through repeated cardioversions (a strategy called rhythm control) is better than simply slowing the heart rate and tolerating AF (rate control). An economic analysis found that rate control cost substantially less per patient and was associated with fewer hospitalizations, pacemaker procedures, and emergency visits.²⁵ More recent trials have shifted the calculus somewhat in favor of early rhythm control, particularly in patients diagnosed within the past year, but the decision remains individualized.

Cardioversion During Pregnancy

Pregnant women who develop AF present a unique challenge: many antiarrhythmic drugs cross the placenta and carry risks to the fetus, making electrical cardioversion an appealing alternative. A review of published cases found that cardioversion was successful in about 93% of pregnant patients after one or more attempts, comparable to or better than the range reported in the general population.²⁶ The procedure has been performed safely at all stages of pregnancy.²⁷

That said, it is not without concerns. A multicenter study found that on two occasions out of 29 cardioversion procedures performed at 26 weeks or later, urgent delivery was required afterward.²⁸ The electrical current itself is unlikely to reach the fetus in a meaningful dose, but the hemodynamic shifts and the sedation can affect both mother and baby. Guidelines recommend performing the procedure in a setting with fetal monitoring available and the ability to proceed to emergency cesarean section if needed.

Adults With Congenital Heart Disease

People born with structural heart defects who survive to adulthood are prone to atrial arrhythmias because of scarring from surgeries, abnormal chamber pressures, and altered anatomy. When AF or atrial flutter develops in these patients, cardioversion works well. A study focused specifically on this population found that cardioversion was successful in 94% of attempts and was safe even in patients with abnormal connections between heart chambers or visible blood sluggishness on imaging.²⁹ For unstable patients in this group, urgent cardioversion remains the first-line approach, just as in the general population.³⁰